On the face of it, I would say this is excellent news for IDEV. The Allergan folks are experts at marketing things that people don't really need (such as yet another OAB drug). Esprit did a horrible job with Sanctura.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.